FDA reviews INOVIO's INO-3107 for rare respiratory disease with potential 2026 approval and ongoing trial collaborations.

INOVIO's Biologics License Application for INO-3107, a treatment for Recurrent Respiratory Papillomatosis (RRP), is under active FDA review with a target approval date of October 30, 2026. The company is preparing for commercial launch and advancing other pipeline candidates, including a glioblastoma trial collaboration with Akeso Inc. INOVIO's current funds are expected to support operations into early 2027, beyond the FDA decision. The company reported a net loss of $19.7 million for Q1 2026 but continues to focus on regulatory progress and commercialization readiness.